# Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

> **NCT02788656** · PHASE4 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 4 (actual)

## Conditions studied

- Congestive Heart Failure

## Interventions

- **DEVICE:** Implantable Hemodynamic Monitor
- **DRUG:** Angiotensin-Converting Enzyme Inhibitor
- **DRUG:** Angiotensin II Type 1 Receptor Blocker
- **DRUG:** sacubitril/valsartan

## Key facts

- **NCT ID:** NCT02788656
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2018-11-09
- **Final completion:** 2018-11-09
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Inadequate Recruitment
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788656, "Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02788656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*